Infliximab Injection, Powder, Lyophilized, For Solution
Product Images NDC 57894-160

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Infliximab (NDC 57894-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Infliximab 01)

This text provides useful information about the percentage of patients who had not lost response in a study comparing placebo maintenance to Infliximab 10 mg/kg and Infliximab 5 mg/kg maintenance. The results suggest that compared to placebo maintenance, Infliximab 10 mg/kg had a p-value of less than 0.001 and Infliximab 5 mg/kg had a p-value of 0.004. The chart shows the study week and maintenance treatment for each group.*

FDA Label Image

Figure 2 (Infliximab 02)

FDA Label Image

Figure 3 (Infliximab 03)

FDA Label Image

Figure 4 (Infliximab 04)

FDA Label Image

Principal Display Panel (100 mg Vial Box)

This text appears to be related to a medication called Infliximab. It includes a recommended dosage and instructions for dilution using a specific type of solution. The medication comes in vials of varying doses and contains sucrose, polysorbate 80, sodium phosphate, and dibasic phosphate. It should be stored at a specific temperature and has a limited shelf life. The name of the company that produces the medication is Janssen Biotech, Inc.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.